BRPI0714553B8 - derivados de camptotecina, processo para preparação dos mesmos, composição farmacêutica e seu uso - Google Patents
derivados de camptotecina, processo para preparação dos mesmos, composição farmacêutica e seu usoInfo
- Publication number
- BRPI0714553B8 BRPI0714553B8 BRPI0714553A BRPI0714553A BRPI0714553B8 BR PI0714553 B8 BRPI0714553 B8 BR PI0714553B8 BR PI0714553 A BRPI0714553 A BR PI0714553A BR PI0714553 A BRPI0714553 A BR PI0714553A BR PI0714553 B8 BRPI0714553 B8 BR PI0714553B8
- Authority
- BR
- Brazil
- Prior art keywords
- preparation
- pharmaceutical composition
- camptothecin derivatives
- camptothecin
- compounds
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940041181 antineoplastic drug Drugs 0.000 abstract 1
- 229940127093 camptothecin Drugs 0.000 abstract 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT001473A ITMI20061473A1 (it) | 2006-07-26 | 2006-07-26 | Derivati della camptotecina ad attivita antitumorale |
| ITMI2006A001473 | 2006-07-26 | ||
| PCT/EP2007/006243 WO2008011994A1 (en) | 2006-07-26 | 2007-07-13 | Camptothecin derivatives with antitumor activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0714553A2 BRPI0714553A2 (pt) | 2013-03-26 |
| BRPI0714553B1 BRPI0714553B1 (pt) | 2020-11-17 |
| BRPI0714553B8 true BRPI0714553B8 (pt) | 2021-05-25 |
Family
ID=38668829
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0714553A BRPI0714553B8 (pt) | 2006-07-26 | 2007-07-13 | derivados de camptotecina, processo para preparação dos mesmos, composição farmacêutica e seu uso |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8217053B2 (enExample) |
| EP (1) | EP2044079B1 (enExample) |
| JP (1) | JP5313894B2 (enExample) |
| KR (1) | KR101412157B1 (enExample) |
| CN (1) | CN101495486B (enExample) |
| AU (1) | AU2007278500B2 (enExample) |
| BR (1) | BRPI0714553B8 (enExample) |
| CA (1) | CA2658900C (enExample) |
| DK (1) | DK2044079T3 (enExample) |
| ES (1) | ES2561356T3 (enExample) |
| HU (1) | HUE027890T2 (enExample) |
| IL (1) | IL196653A (enExample) |
| IT (1) | ITMI20061473A1 (enExample) |
| MX (1) | MX2009000827A (enExample) |
| NO (1) | NO341812B1 (enExample) |
| PL (1) | PL2044079T3 (enExample) |
| PT (1) | PT2044079E (enExample) |
| RU (1) | RU2450008C2 (enExample) |
| SI (1) | SI2044079T1 (enExample) |
| WO (1) | WO2008011994A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10195288B2 (en) * | 2012-10-11 | 2019-02-05 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate |
| EP2910573B1 (en) | 2012-10-19 | 2020-02-19 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate produced by binding through linker having hydrophilic structure |
| KR101586030B1 (ko) * | 2014-01-22 | 2016-01-15 | 주식회사 엘지생활건강 | 캄프토테신을 유효성분으로 포함하는 체모 성장 억제용 조성물 |
| SG11201603960XA (en) | 2014-01-31 | 2016-07-28 | Daiichi Sankyo Co Ltd | Anti-her2 antibody-drug conjugate |
| CA2990572C (en) | 2015-06-29 | 2022-07-26 | Daiichi Sankyo Company, Limited | Method for selectively manufacturing antibody-drug conjugate |
| JPWO2018110515A1 (ja) | 2016-12-12 | 2019-10-24 | 第一三共株式会社 | 抗体−薬物コンジュゲートと免疫チェックポイント阻害剤の組み合わせ |
| SG11201906554RA (en) | 2017-01-17 | 2019-08-27 | Daiichi Sankyo Co Ltd | Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate |
| TWI926682B (zh) | 2017-05-15 | 2026-05-21 | 日商第一三共股份有限公司 | 抗體－藥物結合物之製造方法 |
| SG11202001514XA (en) | 2017-08-31 | 2020-03-30 | Daiichi Sankyo Co Ltd | Novel method for producing antibody-drug conjugate |
| EP3677589B1 (en) | 2017-08-31 | 2025-11-26 | Daiichi Sankyo Company, Limited | Improved method for producing antibody-drug conjugate |
| EP3794042B1 (en) | 2018-05-18 | 2024-03-27 | Daiichi Sankyo Co., Ltd. | Anti-muc1- exatecan antibody-drug conjugate |
| EP3831853A4 (en) | 2018-07-27 | 2022-06-01 | Daiichi Sankyo Company, Limited | ANTIBODY-DRUG CONJUGATE PROTEIN-RECOGNIZING DRUG UNIT |
| IL325918A (en) | 2018-07-31 | 2026-03-01 | Daiichi Sankyo Co Ltd | Antibody-drug conjugates for use in the treatment of metastatic brain tumor |
| US10568873B1 (en) * | 2019-02-14 | 2020-02-25 | United Arab Emirates University | Safranal-sorafenib combination therapy for liver cancer |
| CN112225745B (zh) * | 2020-11-16 | 2021-10-12 | 烟台大学 | 一种具有抗肿瘤活性的异片螺素类化合物、制备方法及用途 |
| CN114805377A (zh) * | 2021-01-29 | 2022-07-29 | 明慧医药（杭州）有限公司 | 适用于抗体-药物偶联物的毒素分子 |
| WO2022262789A1 (zh) * | 2021-06-17 | 2022-12-22 | 明慧医药（杭州）有限公司 | 一种抗肿瘤化合物及其应用 |
| CN117510515A (zh) * | 2022-07-28 | 2024-02-06 | 明慧医药（杭州）有限公司 | 适用于抗体-药物偶联物的毒素分子 |
| WO2024230752A1 (zh) * | 2023-05-08 | 2024-11-14 | 甘李药业股份有限公司 | 喜树碱衍生物、接头、配体-药物偶联物及其医药用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4391909A (en) * | 1979-03-28 | 1983-07-05 | Damon Corporation | Microcapsules containing viable tissue cells |
| US5972955A (en) | 1995-06-06 | 1999-10-26 | Dr. Reddy's Research Foundation | Water soluble C-ring analogues of 20(S)-camptothecin |
| FR2757515B1 (fr) * | 1996-12-20 | 2000-05-05 | Sod Conseils Rech Applic | Formes prodrogues et nouveaux analogues de la camptothecine, leurs procedes de preparation, leur application comme medicaments et les compositions pharmaceutiques les contenant |
| US6881555B2 (en) * | 1999-03-19 | 2005-04-19 | Aventis Pharmaceuticals Inc. | AKT nucleic acids, polypeptides, and uses thereof |
| DE60209517D1 (de) * | 2001-09-25 | 2006-04-27 | Reddys Lab Ltd Dr | Pharmazeutisch geeignete salze von 20(s)-camptothecinen |
| US20060084167A1 (en) * | 2004-10-16 | 2006-04-20 | Cohenford Menashi A | Formation of Hybrid Cells by Fusion of Lineage Committed Cells with Stem Cells |
-
2006
- 2006-07-26 IT IT001473A patent/ITMI20061473A1/it unknown
-
2007
- 2007-07-13 PT PT77860633T patent/PT2044079E/pt unknown
- 2007-07-13 US US12/374,963 patent/US8217053B2/en not_active Expired - Fee Related
- 2007-07-13 JP JP2009521137A patent/JP5313894B2/ja not_active Expired - Fee Related
- 2007-07-13 DK DK07786063.3T patent/DK2044079T3/en active
- 2007-07-13 HU HUE07786063A patent/HUE027890T2/en unknown
- 2007-07-13 AU AU2007278500A patent/AU2007278500B2/en not_active Ceased
- 2007-07-13 RU RU2009102243/04A patent/RU2450008C2/ru active
- 2007-07-13 CN CN2007800283564A patent/CN101495486B/zh not_active Expired - Fee Related
- 2007-07-13 WO PCT/EP2007/006243 patent/WO2008011994A1/en not_active Ceased
- 2007-07-13 EP EP07786063.3A patent/EP2044079B1/en active Active
- 2007-07-13 PL PL07786063T patent/PL2044079T3/pl unknown
- 2007-07-13 BR BRPI0714553A patent/BRPI0714553B8/pt not_active IP Right Cessation
- 2007-07-13 CA CA2658900A patent/CA2658900C/en not_active Expired - Fee Related
- 2007-07-13 MX MX2009000827A patent/MX2009000827A/es active IP Right Grant
- 2007-07-13 KR KR1020097001595A patent/KR101412157B1/ko not_active Expired - Fee Related
- 2007-07-13 ES ES07786063.3T patent/ES2561356T3/es active Active
- 2007-07-13 SI SI200731737T patent/SI2044079T1/sl unknown
-
2009
- 2009-01-16 NO NO20090251A patent/NO341812B1/no not_active IP Right Cessation
- 2009-01-22 IL IL196653A patent/IL196653A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| NO341812B1 (no) | 2018-01-29 |
| CA2658900A1 (en) | 2008-01-31 |
| RU2009102243A (ru) | 2010-07-27 |
| EP2044079B1 (en) | 2015-12-09 |
| ITMI20061473A1 (it) | 2008-01-27 |
| AU2007278500A2 (en) | 2010-09-09 |
| AU2007278500A1 (en) | 2008-01-31 |
| IL196653A0 (en) | 2009-11-18 |
| PL2044079T3 (pl) | 2016-06-30 |
| AU2007278500B2 (en) | 2012-06-07 |
| HK1135691A1 (en) | 2010-06-11 |
| WO2008011994A1 (en) | 2008-01-31 |
| PT2044079E (pt) | 2016-03-09 |
| CN101495486B (zh) | 2013-05-15 |
| CN101495486A (zh) | 2009-07-29 |
| HUE027890T2 (en) | 2016-11-28 |
| ES2561356T3 (es) | 2016-02-25 |
| CA2658900C (en) | 2015-09-15 |
| DK2044079T3 (en) | 2016-02-29 |
| US20100120816A1 (en) | 2010-05-13 |
| IL196653A (en) | 2015-04-30 |
| NO20090251L (no) | 2009-01-16 |
| KR20090033456A (ko) | 2009-04-03 |
| MX2009000827A (es) | 2009-02-03 |
| JP2009544634A (ja) | 2009-12-17 |
| BRPI0714553B1 (pt) | 2020-11-17 |
| JP5313894B2 (ja) | 2013-10-09 |
| RU2450008C2 (ru) | 2012-05-10 |
| US8217053B2 (en) | 2012-07-10 |
| BRPI0714553A2 (pt) | 2013-03-26 |
| KR101412157B1 (ko) | 2014-06-25 |
| EP2044079A1 (en) | 2009-04-08 |
| SI2044079T1 (sl) | 2016-02-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0610850A2 (pt) | derivados de Ácido aril alquila, composiÇço farmacÊutica, medicamento, bem como uso dos referidos derivados | |
| BRPI0720972B8 (pt) | compostos análogos de ciclopamina e composições farmacêuticas compreendendo os referidos compostos | |
| BRPI0513901A (pt) | derivados de uréia cìclicos substituìdos, preparação dos mesmos e uso farmacêutico dos mesmos como inibidores de cinase | |
| BRPI0507198A (pt) | derivados de bisariluréia | |
| BRPI1008473A2 (pt) | compostos heterocíclicos bicíclicos substituídos como moduladores de gama secretase | |
| UY32648A (es) | Nuevos derivados de pirimidina y su uso en el tratamiento de enfermedades | |
| BRPI0408347B8 (pt) | derivados de pirimidina, seu uso, e composição e combinação farmacêuticas | |
| EA200901133A1 (ru) | Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение | |
| BRPI0910388A2 (pt) | agentes terapêutico antivirais. | |
| BRPI0707302B8 (pt) | compostos de cianoisoquinolina que atuam no dano tecidual associado com isquemia, hipóxia e anemia, bem como composição farmacêutica que os compreende | |
| EA200901138A1 (ru) | Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение | |
| BR112012011793A2 (pt) | "acrilamidas heterocíclicas e seu uso como farmacêuticos" | |
| MX384206B (es) | Formulaciones de inhibidores de dpp iv | |
| BRPI0712631A8 (pt) | compostos, processos para a preparação de um composto, composição farmacêutica, uso de um composto e combinações | |
| BRPI0717156B8 (pt) | inibidores do co-transportador 2 da glicose de sódio e composição farmacêutica que os compreende | |
| MY148429A (en) | Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof | |
| BRPI0821004A8 (pt) | Composto derivado de aminopirazol, composição farmacêutica que o contem e uso deste | |
| BR112014023384A2 (pt) | inibidores de bace de di-hidro-tiazina e di-hidro-oxazina espirocíclicos, e composições e usos dos mesmos | |
| BR0315580A (pt) | Derivados de metileno uréia | |
| BRPI0815547B8 (pt) | composição farmacêutica compreendendo depsipeptídeos cíclicos, e seus usos | |
| BRPI0707704A8 (pt) | derivados de antranilamida / 2-amino-heteroareno carboxamida | |
| BRPI0514731A (pt) | derivados de pirimidina | |
| UY30215A1 (es) | Derivados de cromanol sustituidos, procedimientos para su preparacion, composiciones farmacéuticas que los contienen y aplicaciones | |
| BR112012009310B8 (pt) | composto derivados de 2-oxo-1-pirrolidinil imidazotiadiazol, uso dos mesmos e composição farmacêutica compreendendo os mesmos | |
| BRPI1008855B8 (pt) | derivados de indol, seu uso como agentes anticâncer, seu processo para preparação e composição farmacêutica que os compreende |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 17/11/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/07/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 15A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2679 DE 10-05-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |